Last November, during the 3rd round of the Mustafa Prize Award Ceremony, Ugur Sahin was awarded the 2019 Mustafa Prize in Life and Medical Science and Technology for his achievements in “Development and Clinical Testing of mRNA-based Cancer Vaccines that are Tailored to the Mutation Profile of a Cancer Patient.”
Born in Turkey, Sahin is now a professor of oncology and immunology at the University of Mainz in Germany and is the chief executive and co-founder of BioNTech company.
As the world is struggling with the COVID-19 pandemic, the 2019 Mustafa Prize laureate, Ugur Sahin, has come to commendable achievements.
This is a vaccine that hopes to eradicate corona has been discovered by Turkish scientist Ugur Sahin and his wife. This has made his scientific background a hot topic in the media. But the most important point that has been in the center of attention of scientific circles and media in the world is that the most important scientific honor in Ugur Shahin's resume is the "Mustafa Prize" which is awarded every two years to the top scientists in the Islamic world. The award was given to Shahin two years ago for his new method of producing a cancer vaccine, and this new method is now the reason for the vaccine's success.
Shahin's research and actions in producing a new generation of vaccines were unparalleled. Because while the world was working on mass-produced vaccines on DNA, he first used mRNA or RNA messenger to make the vaccine. Vaccine production is done using fourth-generation mRNA and the last generation of vaccines. In this method, instead of manipulating the cell gene, which has dangerous side effects and even carcinogenesis, the virus antigen is produced in the cell ribosome, which has fewer side effects and a higher rate of vaccine production.
A year later, the Mustafa Prize went to Ugur Shahin while he was working on a cancer vaccine. He received the 2019 Biomedical Science and Technology Award for "design and clinical evaluation of mRNA-based anti-cancer therapies."
Shahin and his wife, the founder of BioNTech in Germany. Following the outbreak of the coronavirus worldwide, Biontec quickly focused on producing the coronavirus vaccine, so it was able to receive a lot of funding for this research.
BioNTech and its U.S. partner, Pfizer, are developing an effective COVID-19 vaccine, which has garnered worldwide attention. It is expected that 100 million doses of the vaccine be produced and made available to people by the end of 2020.
DW’s report further notes that the U.S. government has agreed to pay Pfizer and BioNTech nearly $2 billion for their potential Coronavirus vaccine. Due to these developments, the value of BioNTech shares soared to more than €20 billion, making Ugur Sahin a billionaire in Germany.
Type and Press enter